New drug trial aims to shrink spleens and ease suffering in blood cancer patients
NCT ID NCT07317700
Summary
This study is testing whether a new tablet called flonoltinib maleate can help people with intermediate- or high-risk myelofibrosis, a serious bone marrow cancer. About 105 participants will take either the new drug or an existing treatment to see which one better reduces spleen size and improves symptoms like fatigue and abdominal discomfort. The main goal is to see if the new drug can shrink the spleen by at least 35%.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MF are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS)
RECRUITINGTianjin, Tianjin Municipality, 300052, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
West China Hospital Sichuan University
RECRUITINGChengdu, Sichuan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.